Syncona : Autolus Receives FDA Approval For AUCATZYL In Adults With Relapsed/Refractory B-ALL
11/11 08:32
(RTTNews) - Syncona Ltd (SYNC.L) said that its portfolio company Autolus Therapeutics announced that the U.S. Food and Drug Administration has granted marketing approval for AUCATZYL (obe-cel) for the treatment of adult patients with relapsed or refractory B-cell precursor acute...